Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study

International Journal of Antimicrobial Agents

Volumn 29, Issue 3, 2007, Pages 295-301

  Ross, James E ^a   Fritsche, Thomas R ^a   Sader, Helio S ^a,b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Linezolid; MRSA; Non USA; Oxazolidinone; Resistance; Surveillance

Indexed keywords

CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 33846938595     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.09.025     Document Type: Article

References (22)

1. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
2. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin Infect Dis 39 (2004) 1010-1015
3. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
4. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., and Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 26 (2005) 13-21
5. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 49 (2005) 5024-5032
6. Clinical and Laboratory Standards Institute. M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. Wayne, PA: CLSI; 2006.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16. Wayne, PA: CLSI, 2006.
8. Sahm DF, Draghi DC, Blosser RS, Hogan PA, Sheehan DJ. Evaluation of broth microdilution (BMD) and Etest (E) for determining in vitro activity of linezolid (LZ) against S. aureus (SA) and enterococci (EN), Abstr C-320. In: American Society for Microbiology, 105th General Meeting; 2005; Atlanta, GA: ASM; 2005. p. 171.
9. Poppe S, Schaadt R, Sheehan D, Sahm D, Zurenko G, Shinabarger D. Mutation analysis of Staphylococcus aureus isolates demonstrating trailing linezolid (LZD) endpoints in microdilution MIC assays, Abstr A-088. In: American Society for Microbiology, 106th General Meeting 2006; Orlando, FL; 2006. p. 20.
10. ® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57 (2006) 279-287
11. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., and Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 36 (2003) E146-E148
12. Ballow C.H., Jones R.N., and Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 43 (2002) 75-83
13. Bell J.M., Turnidge J.D., Ballow C.H., and Jones R.N. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J Antimicrob Chemother 51 (2003) 339-345
14. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., and Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect 8 (2002) 791-800
15. Brauers J., Kresken M., Hafner D., and Shah P.M. Surveillance of linezolid resistance in Germany, 2001-2002. Clin Microbiol Infect 11 (2005) 39-46
16. Cercenado E., Garcia-Garrote F., and Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 47 (2001) 77-81
17. Gemmell C.G. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 48 (2001) 47-52
18. Mutnick A.H., Biedenbach D.J., Turnidge J.D., and Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 43 (2002) 65-73
19. van de Sande Bruinsma N, Tiemersma E, de Kraker M, et al. Serious developments of antimicrobial resistance in Europe: results from EARSS (European Antimicrobial Resistance Surveillance System). In: 16th European Congress of Clinical Microbiology and Infectious Diseases; 2005; Nice, France; 2005. p. Abstr. P1383.
20. Prystowsky J., Siddiqui F., Chosay J., et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45 (2001) 2154-2156
21. Potoski B.A., Adams J., Clarke L., et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 43 (2006) 165-171
22. College of American Pathologists. Microbiology Surveys Program; Critique for D-05, S. aureus. CAP, Chicago, IL. 2005.